In view of these promising results, a subsequent expansion cohort was started in which gBRCA1/2m, HER2-negative, stage I-III BC patients received neoadjuvant TALA as single-agent during 4 to 6 months, without any chemotherapy, in order to evaluate the pCR rate without chemotherapy and tolerance [28]. Here, ERBB2 is linked to breast cancer.